The ASX edged lower at lunch as oil rose on Black Sea strikes, miners slid and IperionX copped a sharp post-short seller ...
Genetics Signatures says US sales of the company's Easyscreen diagnostics have disappointed, but a revamped strategy should ...
Strong patient demand and expanding trial sites are helping Paradigm progress its long-awaited phase III knee OA study.
Backed by government and industry partners, Micro-X is pushing its cold-cathode X-ray tech toward commercial readiness.
Tylah Tully looks at Vertex Minerals and the increasingly alluring gold grades coming out of its Reward gold mine in New ...
Rare earths and mineral sands hopeful Ark Mines wants to ride a wave of government support to production as soon as 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback